GC
RGNX icon

Globeflex Capital’s Regenxbio RGNX Stock Holding History

Globeflex Capital’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,529
Closed -$431K – 529
2019
Q1 		$431K Buy
7,529
+1,129
+18% +$55.9K 0.09% 312
2018
Q4 		$268K Hold
6,400
– – 0.06% 349
2018
Q3 		$483K Buy
6,400
+800
+14% +$57.6K 0.09% 306
2018
Q2 		$402K Buy
+5,600
New +$267K 0.08% 332

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Globeflex Capital's RGNX Position: Q2 2019 in Review

Globeflex Capital sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 7,529 shares — an estimated $431K sold.

Globeflex Capital first reported a position in RGNX in Q2 2018 and held it in 4 quarters. The position peaked at $483K in Q3 2018. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

  • Globeflex Capital reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
  • Globeflex Capital sold 7,529 Regenxbio shares in Q2 2019, an estimated $431K.
  • Globeflex Capital first reported a position in Regenxbio in Q2 2018 and held it in 4 quarters.
  • Globeflex Capital's Regenxbio position peaked at $483K in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on Globeflex Capital's 13F filing for Q2 2019, filed 12 Aug 2019.